Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease

被引:58
作者
Bharucha, Kersi J. [1 ]
Friedman, Joyce K. [1 ]
Vincent, Andrea S. [2 ]
Ross, Elliott D. [1 ]
机构
[1] Univ Oklahoma Hlth Sci, Ctr & Vet Adm, Med Ctr, Dept Neurol, Oklahoma City, OK 73104 USA
[2] Ctr Study Human Operator Performance, Norman, OK USA
关键词
Parkinson's disease; ceruloplasmin; copper; iron; neurodegenerative; oxidative stress;
D O I
10.1007/s00415-009-0063-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Ceruloplasmin functions as a ferroxidase in iron metabolism. Parkinson's disease (PD) is characterized by an increase in brain iron. We postulated that lower circulating ceruloplasmin levels in PD would result in rapid brain iron accumulation and an earlier age of onset. Consecutive PD patients were separated into subgroups with younger (<= 60 years, n = 62) and older ages of onset (> 60, n = 29), and compared to non-PD controls (n = 40). A one-way ANOVA comparing ceruloplasmin levels showed a very robust effect [F(2,128) = 46.4, p < 1e-99]. Post hoc analysis demonstrated that the younger-onset PD subgroup [22.0 mg/dl +/- 6.5 SD] had a lower mean ceruloplasmin level compared to the older-onset PD subgroup [35.7 +/- 10.4] and controls [35.6 +/- 8.4], whose levels did not differ from each other. Ceruloplasmin levels showed robust correlation with age of onset in all 91 PD patients [r= 0.56, r(2) = 0.31, p < 0.0001] but not in the non-PD controls [r = 0.16, r(2) = 0.03, not significant]. Mode of onset and duration of PD showed no relationship to ceruloplasmin. Serum copper and ferritin, available in most patients, did not differ between the PD subgroups. Younger-onset PD patients have significantly lower levels of serum ceruloplasmin compared to those with older-onset PD. Ceruloplasmin may play a role in the etiopathogenesis of younger-onset PD patients and merits further study.
引用
收藏
页码:1957 / 1962
页数:6
相关论文
共 23 条
[1]   Disturbance of iron metabolism in Parkinson's disease ultrasonography as a biomarker [J].
Berg, D ;
Hochstrasser, H ;
Schweitzer, KJ ;
Riess, O .
NEUROTOXICITY RESEARCH, 2006, 9 (01) :1-13
[2]   Iron metabolism in parkinsonian syndromes [J].
Berg, Daniela ;
Hochstrasser, Helmine .
MOVEMENT DISORDERS, 2006, 21 (09) :1299-1310
[3]   Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease [J].
Boll, MC ;
Sotelo, J ;
Otero, E ;
Alcaraz-Zubeldia, M ;
Rios, C .
NEUROSCIENCE LETTERS, 1999, 265 (03) :155-158
[4]   ALTERATIONS IN THE LEVELS OF IRON, FERRITIN AND OTHER TRACE-METALS IN PARKINSONS-DISEASE AND OTHER NEURODEGENERATIVE DISEASES AFFECTING THE BASAL GANGLIA [J].
DEXTER, DT ;
CARAYON, A ;
JAVOYAGID, F ;
AGID, Y ;
WELLS, FR ;
DANIEL, SE ;
LEES, AJ ;
JENNER, P ;
MARSDEN, CD .
BRAIN, 1991, 114 :1953-1975
[5]   Screening for mutations of the ferritin light and heavy genes in Parkinson's disease patients with hyperechogenicity of the substantia nigra [J].
Felletschin, B ;
Bauer, P ;
Walter, U ;
Behnke, S ;
Spiegel, J ;
Csoti, I ;
Sommer, U ;
Zeiler, B ;
Becker, G ;
Riess, O ;
Berg, D .
NEUROSCIENCE LETTERS, 2003, 352 (01) :53-56
[6]   Determinants of serum copper, zinc and selenium in healthy subjects [J].
Ghayour-Mobarhan, M ;
Taylor, A ;
New, SA ;
Lamb, DJ ;
Ferns, GAA .
ANNALS OF CLINICAL BIOCHEMISTRY, 2005, 42 :364-375
[7]   The relevance of iron in the pathogenesis of Parkinson's disease [J].
Götz, ME ;
Double, K ;
Gerlach, M ;
Youdim, MBH ;
Riederer, P .
REDOX-ACTIVE METALS IN NEUROLOGICAL DISORDERS, 2004, 1012 :193-208
[8]   ACERULOPLASMINEMIA - MOLECULAR CHARACTERIZATION OF THIS DISORDER OF IRON-METABOLISM [J].
HARRIS, ZL ;
TAKAHASHI, Y ;
MIYAJIMA, H ;
SERIZAWA, M ;
MACGILLIVRAY, RTA ;
GITLIN, JD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (07) :2539-2543
[9]   Functional relevance of ceruloplasmin mutations in Parkinson's Disease [J].
Hochstrasser, H ;
Tomiuk, J ;
Walter, U ;
Behnke, S ;
Spiegel, J ;
Krüger, R ;
Georg, B ;
Riess, O ;
Berg, D .
FASEB JOURNAL, 2005, 19 (11) :1851-+
[10]   Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease [J].
Hochstrasser, H ;
Bauer, P ;
Walter, U ;
Behnke, S ;
Spiegel, J ;
Csoti, I ;
Zeiler, B ;
Bornemann, A ;
Pahnke, J ;
Becker, G ;
Riess, O ;
Berg, D .
NEUROLOGY, 2004, 63 (10) :1912-1917